2026 Pharmacy500 Platinum Pages

The Buyer's Guide for Pharmacy Management

138 RXINSIDER | 2026 PHARMACY500 PLATINUM PAGES

MANUFACTURING

• 503B Outsourcing Facilities, Compounding Services

• Contract Manufacturing, Drug Shortage Mitigation

• Generics, Brand Name, Biotech

• Injectables

OVERVIEW

Pharmacy manufacturing encompasses the production of

brand-name, generic, injectable and compounded medications

to ensure the availability of safe and effective treatments. 503B

outsourcing facilities produce bulk compounded medications

for healthcare providers under FDA oversight. Pharmacy

manufacturing increasingly relies on contract manufacturing

organizations (CMOs) and drug shortage mitigation strategies

to ensure a steady supply of medications.

KEY TERMS

• Pharmacy 503B outsourcing refers to a specific type of

pharmaceutical outsourcing facility regulated under Section

503B of the Federal Food, Drug, and Cosmetic Act (FDCA).

It involves the outsourcing of compounded medications by

a pharmacy facility that is registered with the U.S. Food and

Drug Administration (FDA). These pharmacies are authorized

to produce large quantities of compounded drugs for

hospitals, clinics, and other healthcare providers.

• Drug shortage mitigation refers to the strategies and

processes implemented by healthcare providers, pharmacies,

manufacturers, and regulatory agencies to prevent, manage,

and alleviate the impact of drug shortages on patient care.

• Branded pharmaceutical manufacturers are companies that

develop, produce, and market pharmaceutical products under

a proprietary brand name, while generic drug manufacturers

are companies or entitities that produce generic versions of

branded pharmaceutical products once the original drug’s

patent protection expires.

• Injectables include antibiotics, pain management drugs, and

anesthetics administered intravenously or via injection.

Source: U.S. Dept. of Health and

Human Services

of U.S. hospitals report shortages.

99%

of U.S. hospitals obtain

compounded drugs exclusively

from registered 503B

outsourcing facilities.

89%

of pharmaceutical

manufacturing sites are

located in the U.S.

42%

Source: FDA

Source: American Hospital

Association